Long-term effects of cariprazine exposure on dopamine receptor subtypes
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term effects of cariprazine exposure on dopamine receptor subtypes
Authors
Keywords
-
Journal
CNS SPECTRUMS
Volume 19, Issue 03, Pages 268-277
Publisher
Cambridge University Press (CUP)
Online
2013-11-08
DOI
10.1017/s1092852913000680
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy
- (2013) Leslie Citrome ADVANCES IN THERAPY
- Cariprazine in Bipolar Disorder: Clinical Efficacy, Tolerability, and Place in Therapy
- (2013) Leslie Citrome ADVANCES IN THERAPY
- Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview
- (2012) V. V. Dias et al. ACTA PSYCHIATRICA SCANDINAVICA
- Pharmacokinetics and metabolism update for some recent antipsychotics
- (2011) Silvio Caccia Expert Opinion on Drug Metabolism & Toxicology
- Emerging drugs for schizophrenia
- (2011) Falko Biedermann et al. EXPERT OPINION ON EMERGING DRUGS
- Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents
- (2011) István Gyertyán et al. NEUROCHEMISTRY INTERNATIONAL
- The Physiology, Signaling, and Pharmacology of Dopamine Receptors
- (2011) J.-M. Beaulieu et al. PHARMACOLOGICAL REVIEWS
- Current perspectives on the selective regulation of dopamine D2 and D3 receptors
- (2010) Dong Im Cho et al. ARCHIVES OF PHARMACAL RESEARCH
- Cognition and disability in bipolar disorder: lessons from schizophrenia research
- (2010) Philip D Harvey et al. BIPOLAR DISORDERS
- Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
- (2010) Richard Mailman et al. CURRENT PHARMACEUTICAL DESIGN
- Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
- (2010) B. Kiss et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Enhanced cognitive performance of dopamine D3 receptor “knock-out” mice in the step-through passive-avoidance test: Assessing the role of the endocannabinoid/endovanilloid systems
- (2010) Vincenzo Micale et al. PHARMACOLOGICAL RESEARCH
- Antipsychotic Drugs for First-Episode Schizophrenia
- (2009) Kayvon Salimi et al. CNS DRUGS
- Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain
- (2009) Frank I. Tarazi et al. SYNAPSE
- Asenapine induces differential regional effects on serotonin receptor subtypes
- (2008) FI Tarazi et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15
- (2008) István Gyertyán et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
- (2008) J. A. Lieberman et al. PHARMACOLOGICAL REVIEWS
- Differential regional and dose-related effects of asenapine on dopamine receptor subtypes
- (2008) Frank I. Tarazi et al. PSYCHOPHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started